Cerus Corporation to Participate in Upcoming Virtual Investor Conferences

Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference.

On Wednesday, February 16th at 9:00 a.m. EST, Vivek Jayaraman, Cerus’ chief operating officer, is scheduled to participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference. BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

On Friday, February 18th at 12:00 p.m. EST, Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 11th Annual SVB Leerink Global Healthcare Conference. To listen to the webcast, please visit the investor relations section of Cerus’ website at: ir.cerus.com.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Contacts

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.